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Abstract Various studies have shown that the membrane
ectoenzyme dipeptidyl peptidase IV (DP IV, CD26), expressed
on T, NK, and B cells in the human immune system, is involved in
the regulation of DNA synthesis and cytokine production. Here,
we clearly demonstrate that this enzyme is highly expressed also
on human epidermal foreskin and split-skin keratinocytes and
that the specific DP IV inhibitors Lys[Z(NO2)]-thiazolidide,
Lys[Z(NO2)]-pyrrolidide inhibit the enzymatic activity as well as
the DNA synthesis of these cells. These data demonstrate that
CD26 plays a role also in regulation of DNA synthesis of
epidermal keratinocytes and that the enzymatic activity is
required for mediating these effects.
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1. Introduction
The dipeptidyl peptidase IV (DP IV, EC 3.4.14.5) is a trans-
membrane type II glycoprotein that is present on most mam-
malian cells [1,2].
In the immune system, this enzyme is found on T lympho-
cytes, but also on B lymphocytes and NK cells [1,3,4]. DP IV
is a serine peptidase that catalyzes the release of N-terminal
dipeptides from peptides and proteins preferentially with pro-
line, hydroxyproline and alanine at the penultimate position
[5]. In the plasma membrane, DP IV occurs as a dimer with a
total molecular mass of 220^240 kDa. At the 4th Workshop
on Leukocytes Di¡erentiation Antigens a number of mono-
clonal antibodies recognizing DP IV was subsumed under the
term CD26 [6^8].
DP IV/CD26 is also known to be an adenosine desaminase
(ADA) binding protein [9] that interacts with collagen on the
extracellular matrix [10^12] and to be involved in CD3/T cell
receptor (TcR)-mediated signal transduction [13^18].
Using speci¢c inhibitors of DP IV, it was demonstrated that
DP IV is involved not only in the regulation of DNA syn-
thesis, but also in the production of various cytokines by
human CD26-immune cells [19^23].
In the present report, we demonstrate that DP IV/CD26 is
highly expressed on human keratinocytes and that the syn-
thetic reversible inhibitors of DP IV, Lys[Z(NO2)]-thiazolidide
and Lys[Z(NO2)]-pyrrolidide, inhibit the speci¢c enzymatic
activity of human keratinocytes as well as the DNA synthesis
in a dose-dependent manner.
2. Materials and methods
2.1. Cells
Commercially available human foreskin keratinocytes (NHEK,
Clonetics) from adult and neonatal donors and primary human
split-skin keratinocytes (RUM, ROL) from patients undergoing rou-
tine skin transplantation were cultured in serum-free keratinocyte
growth medium (KGM, Promocell, Heidelberg). Pieces of split-skin
obtained through routine skin transplantation were washed twice in
Hank’s balanced salt solution (HBSS, w/o Mg2, Ca2) with HEPES
10 mM (HBSS, Boehringer Ingelheim, Germany), minced, placed der-
mal side down in 0.25% trypsin solution and left overnight at 4‡C. On
the following day, dermis could be easily separated from epidermis
using ¢ne forceps and was placed in HBSS with 2% fetal calf serum
(FCS, Gibco, Deisenhofen, Germany).
After 15 min of vortexing, epidermal cells were passed through a
cell strainer (Falcon, Becton Dickinson, Heidelberg, Germany) to re-
tain corni¢ed cells and upper granular cells, then centrifuged at 900
rpm for 9 min. Finally, cells were seeded at a density of approximately
10 000 cells/cm2 in equilibrated tissue culture £asks (Falcon) with
KGM and stored at 37‡C, 5% CO2-saturated humidity. First medium
change was on day 1, then every alternate day. Cells were passaged at
60^80% con£uence and split in a 1:2^1:3 ratio using 0.025% Trypsin/
0.01%EDTA (Boehringer Ingelheim). Cells from passages 1 to 6 were
examined.
2.2. RNA isolation
In each experiment 5U106 cells were used for RNA preparation by
means of an RNeasy isolation kit provided by Qiagen (Hilden, Ger-
many) following the protocol recommended by the supplier. After the
¢rst round of puri¢cation, contaminating DNA was removed by
DNase I digestion (Boehringer Mannheim, Mannheim, Germany;
20 U/50 Wl reaction, 30 min at 37‡C). The RNA was then subjected
to a second round of puri¢cation by means of RNeasy, and the
resulting RNA was quanti¢ed spectrophotometrically using a Gene-
Quant (Pharmacia LKB, Freiburg, Germany). RNA was aliquoted
and stored ethanol-precipitated at 370‡C until use.
2.3. Reverse transcription
In a ¢nal volume of 20 Wl in each case, 1 Wg of total RNA was
transcribed by 20 units of AMV reverse transcriptase (Boehringer
Ingelheim, Heidelberg, Germany) in the supplied bu¡er with the ad-
dition of 0.5 mmol/l dNTP, 10 mmol/l DTT, 50 mmol/l random hex-
anucleotides (Boehringer Mannheim, Mannheim, Germany) and 50
units of placenta RNase inhibitor (Ambion, Austin, TX, USA) during
a 1 h incubation at 37‡C. The enzyme was inactivated by a 10 min
incubation at 65‡C and the reaction mixture was kept frozen at
370‡C until enzymatic ampli¢cation.
2.4. Enzymatic ampli¢cation
One tenth of the reverse transcription reaction was used as the
template for the ampli¢cation reaction. Twenty ¢ve cycles were per-
formed in an Autogene II (CLF, Emmersacker, Germany) in 50 Wl
reaction bu¡er containing 0.5 units Goldstar Taq-polymerase (Euro-
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gentec, Brussels, Belgium), 0.5 mmol/l dNTP, and 1 Wl of the corre-
sponding RT primer set (Stratagene, Heidelberg, Germany) as recom-
mended by the supplier. The initial denaturing step was for 1.5 min at
95‡C. Each cycle consisted of annealing for 0.7 min at 60‡C, elonga-
tion at 72‡C for 1.0 min, and denaturing at 96‡C for 0.3 min. The
¢nal elongation step was extended to 3.0 min. Ten microliter of each
reaction mixture were loaded on a 1.9% agarose gel and electropho-
resed at 5 V/cm in 1UTBE bu¡er and then stained with ethidium
bromide.
2.5. Synthesis of DP IV substrates and inhibitors
(Gly-Pro)2-Rhodamine 110 was prepared starting from Rhodamine
110 (Synthon AcMaRi Chemie, Wolfen, Germany) by coupling with
t-butyloxycarbonyl (Boc)-proline and Boc-glycine using mixed anhy-
dride method [24]. The Boc-group was removed by treatment with
HCl in acetic acid. The substrate was puri¢ed by HPLC and charac-
terized by mass spectrometry. The DP IV inhibitors Lys[Z(NO2)]-
thiazolidide and -pyrrolidide were synthesized as described previously
[25,26].
2.6. Enzymatic assay
Enzymatic activity of DP IV was determined according to the meth-
od published by Schoºn [27] using 1.6 mM Gly-Pro-4-nitroanilide [28]
and 4U104 cells in the reaction mixture.
2.7. Immuno£uorescence CD26-staining of cells
Indirect immuno£uorescence staining of keratinocytes was per-
formed in ice-cold PBS using the monoclonal anti-DP IV (CD26)
antibody EF5/A3 (IgG1) [29]. Labelled cells were analyzed by £ow
cytometry (FACScan, Becton Dickinson). For control of non-speci¢c
or Fc receptor-mediated labelling, we tested the binding of irrelevant
IgG1 monoclonal antibodies (Coulter Electronics, Krefeld, Germany).
2.8. Enzymatic staining using the DP IV substrate
(Gly-Pro)2-Rhodamine 110, £uorescence microscopy
Keratinocytes were cultured for 72 h on chamber slides (Nunc,
Wiesbaden, Germany) at 37‡C, 5% CO2 in serum-free KGM medium
(CellSystems, Remagen, Germany). For enzymatic staining, 50^70%
con£uent cells were washed, incubated for 30 min at 37‡C with the
DP IV substrate (Gly-Pro)2-Rhodamine 110 (0.02 mM) in presence
and absence of the DP IV inhibitor Lys[Z(NO2)]-thiazolidide (1035
M) and analyzed under a £uorescence microscope (Axiovert, Zeiss,
Oberkochen, Germany).
2.9. Proliferation assay
Keratinocytes (104 cells/100 Wl) were incubated in serum-free KGM
medium in the presence of di¡erent concentrations of the DP IV
inhibitors Lys[Z(NO2)]-thiazolidide, and Lys[Z(NO2)]-pyrrolidide
[22,26]. After 56 h the cultures were pulsed for an additional 16 h
with 3H-methyl-thymidine ([3H]dThd, 0.2 WCi per well ; Amersham,
Braunschweig, Germany). Cells were harvested onto glass ¢ber ¢lters,
and the incorporated radioactivity was measured by scintillation
counting [22].
2.10. Cell viability assay
Cell viability was determined using the EZ4U cell proliferation and
cytotoxicity assay (Biomedica, Wien, Austria).
3. Results
3.1. DP IV RT-PCR, enzymatic DP IV activity and
CD26 antigen expression
To clarify whether DP IV/CD26 is expressed on human
keratinocytes, ¢rst we studied DP IV mRNA levels of the
four keratinocyte preparations NHEK Ad, NHEK Neo,
RUM, and ROL. Enzymatic ampli¢cation was performed
on cDNA derived from 70^80% con£uent cell cultures. Total
RNA was isolated, reverse transcribed, and polymerase chain
reaction (PCR) ampli¢ed using primers speci¢c for DP IV.
DP IV mRNA was found to be expressed on all four cell
populations (Fig. 1).
Viable keratinocytes were further analyzed for enzymatic
DP IV activity. Using Gly-Pro-4-nitroanilide as a substrate,
high DP IV activity was detected on viable cells of all four
preparations (Table 1). The enzymatic activity of these cells
was found to be much higher (three- to ten-fold) than on
resting peripheral blood T cells and close to that of T cells
48 h after PHA stimulation (data not shown). These results
were supported by £ow cytometric studies obtained with the
monoclonal anti-CD26 antibody EF5/A3 (Table 1). All four
keratinocyte preparations expressed the CD26 antigen on the
cell surface.
Furthermore, the enzymatic activity of DP IV was studied
on keratinocytes preincubated for a period of 30 min with
di¡erent concentrations of the DP IV inhibitors
Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide. As
shown in Fig. 2, the DP IV inhibitors were capable of sup-
pressing the enzymatic activity of these cell populations in a
dose-dependent manner.
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Fig. 1. DP IV mRNA levels of human keratinocytes. Enzymatic
ampli¢cation was performed on cDNA derived from 70^80% con£u-
ent cell cultures of the four keratinocyte preparations NHEK Ad
(1), NHEK Neo (2), RUM (3), and ROL (4). Total RNA was iso-
lated, reverse transcribed, and polymerase chain reaction (PCR) am-
pli¢ed using primers speci¢c for DP IV.
Fig. 2. In£uence of DP IV inhibitors on the enzymatic DP IV activ-
ity of human keratinocytes. Enzymatic DP IV activity was measured
on human keratinocytes using the DP IV-speci¢c substrate Gly-Pro-
4-nitroanilide in absence and presence (preincubation 30 min) of dif-
ferent concentrations of the DP IV inhibitors Lys[Z(NO2)]-thiazoli-
dide, and Lys[Z(NO2)]-pyrrolidide. The standard deviation from
triplicates was less than 15%.
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Additionally, NHEK Ad keratinocytes were cultured on
chamber slides in serum-free KGM medium. For enzymatic
staining, 50^70% con£uent cells were washed, incubated for
30 min at 37‡C with the DP IV substrate (Gly-Pro)2-Rhod-
amine 110 (0.02 mM) in presence and absence of the DP IV
inhibitor Lys[Z(NO2)]-thiazolidide (1035 M). As demon-
strated in Fig. 3, the DP IV, expressed on NHEK Ad kerati-
nocytes, catalyzed the hydrolysis of these DP IV substrate
(Fig. 3A). As expected the inhibitor suppressed the enzymatic
DP IV activity of these cells (Fig. 3B).
3.2. DP IV inhibitors suppressed DNA synthesis
We have demonstrated recently that the DNA synthesis of
human PWM-stimulated PBMC and puri¢ed T cells was
strongly inhibited by the synthetic competitive DP IV inhib-
itors Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide
[30].
The e¡ect of DP IV inhibitors on DNA synthesis of human
keratinocytes was determined by incubation of viable cells for
72 h in the presence and absence of various concentrations of
Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-pyrrolidide. As
shown in Fig. 4, the DNA synthesis of all four cell systems
was strongly suppressed.
To exclude possible cytotoxic e¡ects of the DP IV inhibi-
tors, we measured the viability of the cell culture using the
EZ4U assay. In no case the EZ4U assay was impaired by the
DP IV inhibitors (data not shown).
4. Discussion
DP IV/CD26 has been shown to be an activation marker
for various types of immune cells. Surface expression of CD26
is upregulated after mitogenic, anti-CD3 or IL-2 stimulation
of T cells, St. aureus protein stimulation of B cells and IL-2
stimulation of NK cells [1,3,4,27]. Data from several groups
have provided evidence that DP IV plays an integral role in
the regulation of di¡erentiation and growth of lymphocytes
[1,30^32]. Studying the in£uence of speci¢c synthetic inhibi-
tors of DP IV, we and other laboratories have demonstrated
previously that DP IV is involved in the regulation of DNA
synthesis and production of various cytokines in immune cells
[22,30,31,33,34].
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Fig. 4. In£uence of DP IV inhibitors on DNA synthesis of human
keratinocytes. Human keratinocytes (104 cells/100 Wl) were incubated
with di¡erent concentrations of the synthetic DP IV inhibitors
Lys[Z(NO2)]-thiazolidide, and Lys[Z(NO2)]-pyrrolidide. After 56 h,
the cultures were pulsed with 3H-methyl-thymidine for a further 16
h. [3H]dThd incorporation is indicated as mean from three di¡erent
experiments. The values are expressed as % [3H]dThd incorporated
in relation to control cultures without inhibitor ([3H]dThd incorpo-
ration in control cultures: NHEK Ad = 6550 þ 710 cpm; NHEK
Neo = 4520 þ 420 cpm; RUM = 5610 þ 650 cpm; ROL = 4400 þ 380
cpm). The standard deviation from three experiments was less than
18%.
Fig. 3. Enzymatic staining of human keratinocytes using the DP IV
substrate (Gly-Pro)2-Rhodamine 110. NHEK Ad keratinocytes
were cultured for 72 h on chamber slides at 37‡C, 5% CO2 in se-
rum-free KGM-2 medium. For enzymatic staining, 50^70% con£u-
ent cells were washed, incubated for 30 min at 37‡C with the DP
IV substrate (Gly-Pro)2-Rhodamine 110 (0.02 mM) in absence (A)
and presence (B) of the DP IV inhibitor Lys[Z(NO2)]-thiazolidide
(1035 M).
Table 1
CD26 expression and enzymatic DP IV activity
CD26 positive cells
%
Enzymatic DP IV activity
(pkat/106 cells)
NHEK Ad 36 þ 6 61 þ 13
NHEK Neo 25 þ 4 48 þ 10
RUM 34 þ 3 39 þ 5
ROL 33 þ 3 84 þ 7
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Using RT-PCR, £ow cytometry, enzymatic staining and an
enzymatic DP IV assay, here we could show for the ¢rst time
that this enzyme is highly expressed also on human keratino-
cytes. Moreover, the speci¢c DP IV inhibitors Lys[Z(NO2)]-
thiazolidide, Lys[Z(NO2)]-pyrrolidide were found to inhibit
the enzymatic activity of these cells in a dose-dependent man-
ner.
Most importantly, we found that these DP IV inhibitors do
suppress also the DNA synthesis of human keratinocytes dose
dependently.
To determine the speci¢c action of synthetic DP IV inhib-
itors and to exclude cytotoxic e¡ects, we recently studied the
in£uence of Lys[Z(NO2)]-thiazolidide and Lys[Z(NO2)]-piper-
idide on two di¡erent clones of the human histocytic lympho-
ma cell line U937, one expressing high levels (U937-H), the
other low levels (U937-L) of CD26 [23]. Using these cell mod-
els, we could show that Lys[Z(NO2)]-thiazolidide and
Lys[Z(NO2)]-piperidide diminished DNA synthesis and pro-
duction of IL-1L, but increased the secretion of the IL-1 re-
ceptor antagonist (IL-1RA) and of TNF-K in U937-H cells
which strongly express CD26. The inhibitors did not in£uence
the cytokine production in U937-L cells with weak CD26
expression [23]. Thus, because of the speci¢city of these DP
IV inhibitors, their inhibitory activity on cell proliferation
must be considered to be the consequence of a speci¢c inter-
action with the enzyme on the cell surface.
Keratinocytes actively participate in the immune response
and interact with in¢ltrating mononuclear cells, either by re-
leasing pro-in£ammatory cytokines or via intercellular adhe-
sion reactions.
Novelli and colleagues [35] investigated CD26 expression on
keratinocytes, in both normal and pathological skin, using
immunohistochemical techniques. They found only a sporadic
focal CD26 positivity in normal skin. Interestingly, increased
CD26 expression was shown in cutaneous T-cell lymphomas
and in in£ammatory skin diseases, e.g. psoriasis, lichen planus
and spongiotic dermatitis [35]. In this study, keratinocyte ex-
pression of CD26 was not restricted to a speci¢c skin disease.
The authors proposed that CD26 expression is associated with
the presence of a T lymphocyte intraepidermal in¢ltrate and
that the CD26 molecule may function as a keratinocyte acti-
vation antigen.
In our experiments considerable expression of CD26 and
functional activity could be detected on human keratinocytes
in absence of potential sources of cytokines like T lympho-
cytes. As cultured human keratinocytes are in a highly pro-
liferative activated state, partially due to special media ingre-
dients, i.e. low Ca2 concentration (0.15 mM), our
observations correspond well to Novelli’s.
Taken together, our results suggest that DP IV plays a
crucial role in the regulation of DNA synthesis and cellular
proliferation in cultured human keratinocytes of di¡erent ori-
gin. Further investigation is needed not only to determine the
function of CD26 expression in keratinocytes but to illumi-
nate CD26 activity by keratinocytes in di¡erent environments
and i.e. in£ammation or wound repair in skin related proc-
esses.
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